#cancer therapy #Public Offering #Intensity Therapeutics #Shelton

Intensity Therapeutics Unveils Public Offering

SHELTON, Conn., June 11, 2025 - Intensity Therapeutics, Inc. (Nasdaq: INTS), a company at the forefront of creating innovative cancer therapies, has revealed important details about its latest public offering. Focused on revolutionizing how tumors are treated, Intensity is bringing in funds that will primarily target the efficiency of their groundbreaking intratumoral cancer treatments.

In a move to enhance their research capacity, the company has priced an offering of 6,675,000 shares of its common stock at $0.30 per share, amounting to gross proceeds of approximately $2 million before deducting any expenses or commissions. The company is solely offering these shares, indicating a strategic approach to maintain control over the capital raised. Moreover, they have provided underwriters with a 45-day window to acquire an additional 1,001,250 shares, which ensures coverage for over-allotments in the offering.

This public offering, set to conclude on June 13, 2025, is subject to standard closing conditions. The proceeds garnered will be utilized to enroll additional patients in critical clinical trials, support ongoing studies, and for general operational expenses, showcasing a well-rounded funding strategy aimed at fostering advancements in cancer treatment.

Innovative Cancer Therapeutics
Intensity Therapeutics specializes in novel immune-based intra-tumoral therapies designed specifically to attack and kill tumor cells while enhancing the body’s immune response against cancer. Their flagship investigational drug, INT230-6, demonstrates promising results in clinical trials by eradicating tumors and promoting an adaptive immune response within a matter of days post-injection. This innovative approach could redefine the paradigm of cancer care, transforming aggressive malignancies into manageable chronic conditions.

The company has completed multiple clinical trials involving over 200 patients, all aimed at examining the efficacy of INT230-6 across various cancer types, including metastatic cancers and locally advanced breast cancer. Currently, Intensity has moved ahead with a Phase 3 trial focusing on soft tissue sarcoma (the